NEW YORK (GenomeWeb) – Agilent Technologies today announced that it will provide access to its bioanalytical instruments to National University of Singapore Yong Loo Lin School of Medicine (NUS Medicine) for use in a study of patient responses to cardiovascular medicines.
Under the terms of their arrangement, the school's department of medicine will have access to Agilent's proof-of-concept laboratory in Singapore, which includes its 6550 iFunnel quadrupole time-of-flight liquid chromatography mass spectrometry system, as well as its Capillary Electrophoresis System model 7100.
Using the technologies, NUS Medicine researchers aim to provide real-time readouts for patients to understand the risks and benefits of commonly prescribed medications throughout the lifecycle of a drug, Agilent said. The effort is beginning with heart disease therapeutics, but could later expand to other conditions such as diabetes.
"Agilent's broad range of technologies will ultimately aid in the development of new analytics for personalized patient care," NUS Medicine professor Chester Drum said in a statement. "Consideration of the patient as an individual, rather than a statistic, is where we will see the next innovations in cardiovascular medicine."
Agilent said that as part of the deal it and NUS Medicine will have opportunities to present at various industry or Agilent-led events and seminars in the Asia-Pacific region.